Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 2023
Date Filed: January 6, 2023
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the company likely has no revenue, but this specific filing does not contain financial statements or quantitative metrics.
Material Changes
The primary material change disclosed in this filing is an ADS ratio change, submitted as Exhibit 99.1. No other material changes versus prior periods are detailed in the text provided.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, specific risk factors, or contingencies. The document serves primarily to incorporate the ADS ratio change into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the specific details of the ADS ratio change referenced in Exhibit 99.1.
- Confirm the impact of the ADS ratio change on existing shareholdings and trading prices.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for broader context on capital structure.
- Check subsequent filings for the company's cash position and burn rate, as this filing does not provide liquidity data.